retatrutide clinical trial duration Looking forward to when #retatrutide's Phase 3 results will become available. There are are 4 planned TRIUMPH trials investigating retatrutide's efficacy in treating obesity and its complications: #type2diabetes #cardiovascular disease Retatrutide Phase 3: TRIUMPH Program

Carracedo, A

The dysplasia may be adenoma-like (villous growth with elongated, hyperchromatic, and pseudostratified nuclei, with frequent mitosis and apoptotic bodies, similar to those in colorectal adenomas), serrated dysplasia (with serrated crypts, lined by cuboidal cells to low columnar cells with large hyperchromatic nuclei, low cytoplasmic mucin, and numerous mitoses), or a serrated adenoma-like dysplasia (with complex serrations and villous growth

Keywords: tirzepatide, postmarketing surveillance, drug safety, adverse events Introduction Tirzepatide, a novel dual agonist targeting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors marketed as Zepbound by its manufacturer Eli Lilly and Company, has shown significant efficacy in managing type 2 diabetes mellitus (T2DM) and obesity, as demonstrated in key clinical trials such as SURPASS [1] and SURMOUNT [2]

Understanding these mechanisms may provide new targets for interventions aimed at mitigating age-associated diseases

Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM